CME/CNE Podcast


Our podcast feature expert reviews of recent articles and discuss clinical applications of the findings. Listen to expert commentary and earn CME/CNE Credit!

This section offers downloads of audio files. If you do not have a Media Player, you can acquire one by clicking one of the following:

iTunes Download Windows Media Player® iTunes Download iTunes®

Expert Insight:
Evaluating the Efficacy of Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis

Review this case and listen to how the expert faculty would address the scenario.

Expert commentary by:
Robert A. Bermel, MD
Mellen Center for Multiple Sclerosis
Cleveland Clinic






Comprehensive Care in Multiple Sclerosis

Presented by:
Susan E. Bennett, PT, DPT, Ed.D, NCS, MSCS
University at Buffalo, SUNY

Patty Bobryk, MHS, PT, MSCS, ATP
MS Comprehensive Care Center of Central Florida






Evaluative Measures and Assessments in Patients with MS

Presented by:
Susan E. Bennett, PT, DPT, Ed.D, NCS, MSCS
University at Buffalo, SUNY

Christine Smith, OTR/L
Holy Name Medical Center






Mobility Issues in Multiple Sclerosis

Presented by:
Susan E. Bennett, PT, DPT, Ed.D, NCS, MSCS
University at Buffalo, SUNY

Patty Bobryk, MHS, PT, MSCS, ATP
MS Comprehensive Care Center of Central Florida






Assistive and Adaptive Devices for Patients with MS

Presented by:
Patty Bobryk, MHS, PT, MSCS, ATP
MS Comprehensive Care Center of Central Florida

Christine Smith, OTR/L
Holy Name Medical Center






The Effect of Cognition on Rehabilitative Assessment and Intervention

Presented by:
Patricia Bednarik, MS, CCC-SLP, MSCS
University of Pittsburgh






Speech, Swallowing, and Oral Care in MS

Presented by:
Patricia Bednarik, MS, CCC-SLP, MSCS
University of Pittsburgh





Looking Ahead–Future Approaches to Rehabilitation

Presented by:
Susan E. Bennett, PT, DPT, Ed.D, NCS, MSCS
University at Buffalo, SUNY

Lacey Bromley, PT, DPT, NCS, MCSC
Susan E. Bennett PT and Associates





Emerging Therapies and New Approaches to MS Management

Presented by:
Joseph R. Berger, MD, MPH
Perelman School of Medicine, University of Pennsylvania

Patricia K. Coyle, MD
Stony Brook University





Recent Developments with Currently Approved Disease Modifying Therapies

Presented by:
Joseph R. Berger, MD, MPH
Perelman School of Medicine, University of Pennsylvania

Patricia K. Coyle, MD
Stony Brook University




The following activities are no longer available for credit

Myelinating Oligodendrocytes Derived from Primary Progressive MS Patients: Scientists Developed Faster, More Efficient Methodology

Presented by:
Valentina Fossati, PhD
The New York Stem Cell Foundation

David McKeon
The New York Stem Cell Foundation

References:
Douvaras P, Wang J, Zimmer M, et al. Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. Stem Cell Reports. 2014;3(2):250-259.

Talan J. Myelinating Oligodendrocytes Derived from Primary Progressive MS Patients: Scientists Developed Faster, More Efficient Methodology. Neurology Today. 2014;14(17):1,10-12.





NARCRMS

Presented by:
Kottil W. Rammohan, MD
The Multiple Sclerosis Center at the University of Miami

References:
www.narcrms.org/aboutnarcrms.html
www.delmedgroup.com/daily/Rammohan.html





Estriol plus Glatiramer Acetate Study (AAN)

Presented by:
Rhonda Voskuhl, MD
UCLA School of Medicine

Reference:
Voskuhl R. A Combination Trial of Estriol Plus Glatimer Acetate in Relapsing-Remitting Multiple Sclerosis. Neurology. 2014;82(10S):S23.003.





Defining the Clinical Course of Multiple Sclerosis: The 2013 Revisions

Presented by:
Joseph R. Berger, MD
University of Pennsylvania

Fred D. Lublin, MD, FAAN, FANA
Icahn School of Medicine at Mount Sinai

Reference:
Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-286.





MS Disease Activity in RESTORE: A Randomized 24-week Natalizumab Treatment Interruption Study

Presented by:
Guy J. Buckle, MD, MPH
Shepherd Center

Robert J. Fox, MD
Cleveland Clinic Foundation

Reference:
Fox RJ, Cree BA, De Sze J, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82(17):1491-1498.





Early MS/CIS/RIS

Presented by:
Guy J. Buckle, MD, FAAFP
Harvard Medical School

References:
Okuda DT, Mowry EM, Cree BA, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011;76(8):686-692.
http://www.ncbi.nlm.nih.gov/pubmed/21270417

Okuda DT, Mowry ET, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72(9):800-805.
http://www.ncbi.nlm.nih.gov/pubmed/19073949




Switching Therapy and JCV

Presented by:
Guy J. Buckle, MD, FAAFP
Harvard Medical School

References:
Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
http://www.ncbi.nlm.nih.gov/

National Institute of Neurological Disorders and Stroke (NINDS) Progressive Multifocal Leukoencephalopathy Information Page
http://www.ninds.nih.gov/

NINDS Lab Helps Track a Viral Brain Disease
http://www.ninds.nih.gov/

Bellizzi A, Nardis C, Anzivino E, et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol. 2012;18(1):1-11.
http://www.ncbi.nlm.nih.gov/

Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ. JC virus antibody status underestimates infection rates. Ann Neurol. 2013;74(1):84-90.
http://www.ncbi.nlm.nih.gov/




Recent Advances in Treating Multiple Sclerosis: Efficacy, Risks and Place in Therapy

Presented by:
Michael D. Kaufman, MD
Carolinas Medical Center

Reference:
Jeffery DR. Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy. Ther Adv Chronic Dis. 2013;4(1):45-51.
http://www.ncbi.nlm.nih.gov/pubmed/23342246




Monitoring and Improving Patient Adherence to Therapy

Presented by:
Lynn Stazzone, RN, MSN, NP
Brigham & Women's Hospital

Reference:
Ford CC, et al. The Science of MS Management: Monitoring and Improving Patient Adherence to Therapy. 2013.
http://www.mscare.org/?page=cpe_08. Accessed October 2013.




Vitamin D Status Predicts New Brain Magnetic Resonance Imaging Activity in Multiple Sclerosis

Presented by:
June Halper, MSN, APN-C, MSCN, FAAN
Consortium of Multiple Sclerosis Centers and the International Organization of Multiple Sclerosis Nurses

Reference:
Mowry EM, et al. Vitamin D Status Predicts New Brain Magnetic Resonance Imaging Activity in Multiple Sclerosis. Ann Neurol. 2012;72(2):234-240.
http://www.ncbi.nlm.nih.gov/pubmed/22926855